Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer

Affiliations

¹ Pancreas Translational and Clinical Research Center, Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
² Methodology for Clinical Research Laboratory, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Comment

Michele Reni et al. JAMA Oncol. 2023.

. 2023 Mar 1;9(3):435-436.

doi: 10.1001/jamaoncol.2022.7358.

¹ Pancreas Translational and Clinical Research Center, Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
² Methodology for Clinical Research Laboratory, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

No abstract available

Comment in

Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer-Reply.
Conroy T, Castan F, Hammel P. Conroy T, et al. JAMA Oncol. 2023 Mar 1;9(3):436-437. doi: 10.1001/jamaoncol.2022.7361. JAMA Oncol. 2023. PMID: 36701135 No abstract available.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. N Engl J Med. 2018. PMID: 30575490 Clinical Trial.